RxDoctor Payments Data

Trung Pham, DO

Family Medicine · Tulsa, OKNPI 1700851052

Payments from drug & device makers

$2,979in general payments, 2019–2025

Across 87 payments — averaging $34.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$994
  • Amgen$548
  • Lilly USA, LLC$255
  • AstraZeneca$224
  • Phathom Pharmaceuticals, Inc.$167
  • Integra Lifesciences Corporation$134
  • plus $657 from 16 others

What the payments were for

  • Food & beverage$2,979100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,979 in reported general payments places this provider in the 75th percentile of 1,730 family medicine providers in Oklahoma.

See all family medicine providers in Oklahoma

Medicare billing

Part B allowed, 2024
$73,405
Medicare patients
135
Services billed
923

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide42$55,475
MounjaroTirzepatide25$33,406
Trelegy ElliptaFluticasone/Umeclidin/Vilanter49$32,748
EliquisApixaban39$27,407
TrulicityDulaglutide14$24,225
LinzessLinaclotide11$16,832
Janumet XrSitagliptin Phos/Metformin Hcl13$16,058
JanuviaSitagliptin Phosphate15$11,109
Omeprazole201$4,468
Rosuvastatin Calcium341$4,382
SymbicortBudesonide/Formoterol Fumarate12$4,375
Humalog Mix 75-25Insulin Lispro Protamin/Lispro15$3,751
Lantus SolostarInsulin Glargine,hum.Rec.Anlog15$3,443
Celecoxib40$2,997
Amlodipine Besylate465$2,507

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity, Humalog Mix 75-25$255$61,38354 claims
GSKTrelegy Ellipta$994$32,74849 claims
PfizerEliquis$40$27,40739 claims
AbbVieLinzess$30$16,83211 claims
AstraZenecaSymbicort$224$4,37512 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,730 family medicine providers in Oklahoma.

Other family medicine in Tulsa

See the full list for Oklahoma

Where these figures come from

Is this you, or does something look wrong? →